Imagine a world free from HIV…

Imagine a world free from HIV

I once had the privilege of working in an HIV testing/counseling center. Prior to that time, I only had a limited overview of what this disease was and how much people were affected. From time to time, I would visit the phlebotomy laboratory where blood collection was done to carry out CD4 tests and viral load and I would see a long queue of people. I started to get curious because I didn’t want to believe that the number of HIV patients was so much on the rise.

One good day, it was my turn to be in the blood collection table and it was so hectic. There was no breathing space as we had a large pool of patients both for rapid tests and cd4 count. In the midst of my busy day, I saw a woman walk in with a baby strapped at her back and another 2 year old. All through my days in that laboratory, I had not seen a baby or a two-year old child tested positive. It broke me to even find out that the mother was not taking all the necessary measures to take care of those children and even herself. I had tears in my eyes as I imagined a world where these children could be free from HIV.

HIV is a major public health problem around the world and the need for an HIV vaccine cannot be overemphasized. It would not only save this generation but it would keep generations to come from seeing the horrible sight of a child that could be spared of HIV infection if only there was a permanent way out like a vaccine.

HIV management has made commendable progress since the identification of the disease: awareness and prevention programs, development of anti-retroviral drugs to contain the effect of the infect, funding and aids channeled towards helping the larger population of developing countries to manage this disease. It is time we kick this disease out finally.

Imagine a world where about 36 million people currently infected with HIV would be able to live life and be free. A world where allocation of funds towards HIV projects would be diverted towards other social and economic development projects. A world where a mother will not have to live in regret for infecting her child with a permanent virus. A world where love partners wouldn’t have to go their separate ways just because one partner is infected. A world where there wouldn’t be a need for stigmatization.

Imagine a WORLD FREE FROM HIV.

The World needs HIV vaccine

The World needs HIV vaccine

The World needs HIV vaccine
Inline image
 

By Chinye Osa-Afiana

The hype on HIV has been ongoing for several years, and it’s no surprise that the need for a vaccine is gaining same popularity.

It would be so easy to give a long essay on the need and importance of this vaccine, but personally, I have questions to ask my teenage self. As a teen, would I readily take the HIV vaccine if it was made available? I honestly doubt it.

First of all, I’m very sure my mum would say a huge NO!! This could mean a license to engage in illicit sex. Also, there’s the fear of needles and the concern on the frequency of the vaccine intake. But then, this is just me.

It’s easy to take solace in ignorance and absolve oneself from taking responsibility of certain life-altering issues. This is seen in our attitude towards going the extra mile to think of solutions to long standing issues, we most times do not care as long as we are not directly affected. But then, as it concerns HIV, the devastating trail of bodies it has left in its wake as the years go by has prompted the outcry for investments into finding a lasting solution to this menace.

One can only imagine how far this pursuit to a lasting solution has come, as there are still many getting infected and dying from HIV infection.

Google was kind enough to provide this concise info.

But then, all hope is not lost. Yes. There is hope; concerned individuals, institutions and various governments are partnering up to provide a lasting end to this menace in the form of a vaccine.

The question now is; how have you contributed to the end of the spread of the virus? How have you tried to increase your knowledge about the search for the vaccine? How have you helped a friend, neighbor or stranger to be more aware on the work done to finding a cure to AIDS? Above all, will you readily let go of myths & cultural beliefs to receive a HIV vaccine, if made available?

Like in the case of small pox and polio, this vaccine can also give back confidence to all affected directly or indirectly by the disease.

My good friend google to the rescue!!!

It is no longer a thought, or an imagination, or a far-fetched idea of an idealist. It is real. And it is happening now. Join the crusade in increasing the awareness for HIV vaccine in your community. A little word here, a little word there, will eventually go viral, causing the appropriate persons to take heed of our concerns. I personally, will no longer live under the shackles of myths and cultural beliefs concerning vaccines.

I choose to break free of these unseen chains. I choose to be guided by accurate information. And I choose to make informed decisions that will impact positively on members of my community.

The world needs a vaccine. Africa needs a vaccine. Nigeria needs the vaccine.

How can you contribute???

HIV Vaccines: Time to do what we need to do

HIV Vaccines: Time to do what we need to do

HIV Vaccines: Time to do what we need to do
Inline image

By Jennifer Anyanti MPH

Deputy Managing Director, Society for Family Health

It is interesting how the focus is once again shifting from placing all on treatment to continuing the search for the HIV Vaccine. Everywhere it has been proven that vaccines are more cost effective than treatment, in fact as the adage goes, ‘prevention is better than cure’.

The advantages of a vaccine are innumerable, including the fact that they are reducing the need for expensive social and behavioural change messages which, while necessary, tend to be quite expensive.

These are funds that could be shifted into purchasing more vaccines, and allow governments and non-governmental actors to address other areas of programing, including strengthening supply chains which will favour other areas of health.

In addition, the vaccine can target children, and infants that may become infected due to MTCT, which in countries like Nigeria, is still proving to be a tough nut to crack with less than 50% of those who need treatment being on treatment.

Also, in view of the challenges with funding health care in Nigeria and reaching the numbers in the Abuja declaration of 15% for health (http://www.who.int/healthsystems/publications/abuja_declaration/en/), Nigeria was still at less than 5%, except in one state (https://www.dailytrust.com.ng/2018-budget-bauchi-allocates-18-8-to-education-15-23-to-health-sectors.html) and as a result more funds can be used to address the plethora of diseases yet to be addressed in Nigeria.

Despite the advantages inherent in having a vaccine, some key issues need to be addressed. As stated by Gary J. Nabel of the Vaccine Research CenterNIH, in Bethesda, Maryland, a number of areas must be taken into consideration before scientific research will culminate in a definitive AIDS vaccine.

These include the need for greater translation between animal models and human trials and the fact that new, more effective, and more easily produced vectors must be identified.

It is also obvious that the understanding of the immune response to potential vaccine candidates is still yet to be clear.

In addition, in Africa which is still the worse continent affected by the epidemic, insufficient work is being done on research into a vaccine, apart for trials, which are more often than not externally funded.

The need to collaborate strongly with African institutes of research and community advocates cannot be over emphasized.

Also, the issues that also affect vaccination in general such as supply chains, strategic behavioral communication for change and training of health workers will also require consideration and planning.

The hope is that an effective vaccine for HIV could be completed in the next few years (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401528/). Well, millions of those affected or at risk of being affected by HIV are waiting with bated breath.

 

Understanding diversity in vaginal microbiomes: A gateway to an effective HIV vaccine

Understanding diversity in vaginal microbiomes: A gateway to an effective HIV vaccine

Understanding diversity in vaginal microbiomes: A gateway to an effective HIV vaccine
Inline imageInline image

By Constancia Mavodza, Sexual and Reproductive Health and Rights (SRHR) Research Analyst, Global Health Corps Fellow at the Centre for Health and Gender Equity (CHANGE) and Kate Segal, SRHR Policy Analyst, Global Health Corps Fellow at CHANGE.

An exciting emerging research canon that identifies links between vaginal bacteria and HIV underscores the need to prioritize women’s participation in HIV vaccine research. Because HIV passes through the vaginal lining and the female genital tract has a larger surface area than male genitalia, women face greater risk of HIV transmission from heterosexual vaginal intercourse.

But getting women in the door for clinical trials is difficult. Building trust with researchers and providers as well as structural disadvantages and societal barriers inhibit their participation in particular ways. For effective HIV prevention methods and an eventual vaccine, it is particularly important to recruit a diverse group of women – including pregnant women – for HIV vaccine clinical trials. Women’s inclusion in HIV vaccine research recognizes the unique biological factors that increase their HIV risk and ensures that women will receive evidence-informed care.

Adolescent girls and young women aged 15-24 comprise 60 percent of youth living with HIV globally, and in sub-Saharan Africa, adolescent girls and young women account for 74 percent of new HIV infections among youth. Discussions around risk reduction for this group have largely centered on behavioral indicators of adolescent girls and young women, such as having intergenerational sex. While certain behaviors can put girls and women at greater risk of HIV, focusing solely on social and behavioral drivers can veer into moral policing of sexual proclivities that is acutely gendered, particularly because some women cannot negotiate condom use and/or monogamy.

Physiological composition and biological mechanisms in HIV infection are different for men and women. For instance, there are sex-specific differences in HIV viral loads and CD4 counts, as well as in adverse responses to antiretroviral therapy. For adolescent girls, inflammation of the genitalia and greater presence of mucus in the immature cervix increase their vulnerability.

Another biological factor that makes women distinctively susceptible to HIV acquisition is the vaginal microbiome. The vaginal microbiome, or bacterial communities in the vagina, has been found to both increase and decrease HIV risk, depending on a woman’s bacterial makeup.

A recent study of six Eastern and Southern African countries identified seven types of vaginal bacteria that, when highly concentrated, are associated with increased vulnerability to HIV acquisition. It also found that women who acquired HIV had more diversity of bacteria in the microbiome. These findings were consistent for pregnant and post-partum women, female sex workers, and women in serodiscordant relationships (where only one partner is living with HIV).

The vaginal microbiome has also been found to impact the efficacy of antiretroviral drugs for HIV prevention. Results from a clinical trial of one microbicide found that for women whose microbiomes have a high prevalence of one particular bacteria, Lactobacillus, the medicine had significantly higher efficacy than for women in whom this bacteria is not dominant. Relatedly, women with a higher presence of Lactobacillus bacteria were associated with a lower risk of HIV infection.

What’s more, this study found regional differences in women’s vaginal bacteria concentrations: 90 percent of white women in developed countries had Lactobacillus-dominant microbiomes, compared with the majority of women from South Africa, who exhibited low Lactobacillus presence. That geography can be a determinant of your HIV risk indicates that behavioral and social factors can only explain so much, and including a diverse group of women — with diverse microbiomes — in clinical research is key to developing an effective vaccine that is suited to all populations.

Biological changes that happen during pregnancy may also heighten women’s vulnerability to HIV. Two studies found that for African HIV-negative women that are pregnant and in sexual relationships with men living with HIV, the risk of HIV transmission per sex act increased throughout pregnancy, and was highest during the six-month post-partum period. Relative to risk of HIV acquisition when not pregnant, which is approximately five percent, the studies found that the risk of infection was 2.91 times higher during the first trimester, 2.97 times higher during the second two trimesters, and 4.18 times higher post-partum. A biological mechanism called vaginal thinning, which takes place throughout pregnancy, could be the reason pregnant and post-partum women are more susceptible to HIV.

We have an opportunity to acknowledge the diversity of women’s bodies in HIV vaccine research and come up with solutions that are reflective of this complexity. Evidence that the vaginal microbiome and vaginal thinning affect women’s chances of acquiring HIV and response to HIV prevention drugs rightfully disrupts harmful narratives that concentrate too heavily on women’s sexual behavior.

Without accounting for women and the incredible variation in vaginal microbiomes, an effective HIV vaccine will remain out of reach. HIV clinical trials must include women to understand the factors that put particular groups at greater risk of HIV.

As 2018 Civil Society Accountability Forum in Nigeria holds in November, can government be accountable to its promises? – Dr. Folayan

By Morenike Oluwatoyin Folayan

The 2018 edition of the Civil Society Accountability Forum is scheduled to hold on the 13th to 15th of November, 2018 in Abuja, Nigeria. The theme for this year’s conference is “Domestic Resource Mobilisation: Public and Private Sector Investment”.The government – national, state and local – is expected to discuss domestic financing of the HIV response in Nigeria at the forum. This comes up closing on the heels of the commitment made by the Minister of Health, Prof Isaac Adewole at the PEPFAR 2018 COP meeting in Johannesburg, South Africa where he committed to performing a miracle by getting the Nigeria government to take substantial responsibility of the HIV treatment programme by funding procurement of commodities for the response.

He made this statement on the 22nd of February 2018 at the closing of the five days PEPFAR 2018 COP planning meeting.Adewole noted that like South Africa, Nigeria should be leading its National Response and donors should only be complimenting the response. Sadly, this is the reverse.

Nigeria currently funds less than 20% of the National HIV response. The country also has no strategic plans on how it plans to transit the currently heavily PEPFAR and Global Fund subsidized response.The country also has no annual plan that monitors how stakeholders strategically contribute to meeting set targets for the elimination of new HIV infections in the country.

Nigeria has one of the highest number of new HIV infection in Sub-Saharan Africa – in 2016, over 200,000 persons were infected with HIV (https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/nigeria).In an effort to reposition the country, the Ministry of Health (NASCP) conveyed a meeting in Lagos in March 2018, to begin preliminary discussions on national funding of the HIV treatment in Nigeria. This is essential as there are current efforts to phase out the use of Efavirenz and replace this with Dolutagravir.

PEPFAR is already going ahead with the plan to switch therapy. Dolutagravir is more user-friendly, with less side effects and cost effective. The Civil Society under the leadership of Treatment Action Movement in collaboration with Afrocab, had been very active with pushing the country to switch therapy. This was one of the agenda for discussion at the 2016 Civil Society Accountability Forum.

The NASCP meeting not only focused on how to re-establish the national HIV treatment programme, but it also developed a roadmap for the prevention of mother to child transmission of HIV in Nigeria. The roadmap was to have been presented to the Minister by the end of March 2018.
Unlike the Federal Ministry of Health, the National Agency for the Control of AIDS under the leadership of Dr Sani Aliyu, is focused not just on preventing mother to child transmission of HIV, but eliminating it in line with its 2017-2021 HIV and AIDS strategic plan. Nigeria contributes significantly to the global HIV epidemic having the highest number of babies born with HIV in the world. This is partly because only 30% of mothers living with HIV actually have access to HIV treatment programmes that can reduce the risk of mother to child transmission of HIV infection.

With the Minister committing to performing a miracle with the national HIV treatment programme before the coming in of a new government in 2019; and the National Agency for the Control of AIDS focusing its resources to eliminate mother to child transmission of HIV in Nigeria, it is critically important to listen to how the government has fared to date knowing 2020 is a miracle year for all – when AIDS should cease to be a global epidemic.Can Nigeria keep its global commitment to the 2020 goal? We look forward to answers at the 2018 Civil Society Accountability Forum.

Folayan is of New HIV Vaccine and Microbicide Advocacy Society